‏Israel Biotech Fund‏ ‏‏ תמונת נושא
Israel Biotech Fund

Israel Biotech Fund

Biotechnology Research

מעקב

עלינו

Israel Biotech Fund – Building the future of Israeli Biotech Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs at or near clinical stages. Our partners include two top-tier international pharmaceuticals companies, institutional investors, family offices and high net worth individuals. Our key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support. We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance. We provide our portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities. The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value. Team General Partners: David Sidransky, M.D., co-founder and general partner of Israel Biotech Fund. Yuval Cabilly, Ph.D., co-founder and general partner of Israel Biotech Fund. Ido Zairi, co-founder and general partner of Israel Biotech Fund. Venture Advisors Our key members include: Sol Barer, Ph.D., former Chairman and CEO of Celgene, currently serves on the board of several Biotech companies, including TEVA. Jeff Kindler, former Chairman & CEO of Pfizer. Robert Spiegel, MD, former Chief Medical Officer of Schering-Plough. Murray A. Goldberg, former CFO of Regeneron.

אתר אינטרנט
ibf.fund
תעשייה
Biotechnology Research
גודל החברה
2-10 עובדים
סוג
שותפות
התמחויות

עובדים ב- Israel Biotech Fund

צפייה בכל עובדים

עדכונים

  • צפייה בדף הארגון של ‏Israel Biotech Fund‏
    Israel Biotech Fund

    ‏‏2,105‏ עוקבים‏

    Israel Biotech Fund joins its portfolio company, Vensica Medical, and CEO Avner Geva in welcoming Dr. Roger Dmochowski as CMO. It is a real privilege having you join the team Roger. Best of luck.

    צפייה בפרופיל של ‏Avner Geva‏
    Avner Geva

    Co-Founder & CEO @ Vensica Medical | Co-Founder @ IntraGel Therapeutics | Entrepreneur in Residence @ Yale Ventures

    I am thrilled to officially welcome Dr. Roger Dmochowski to Vensica Medical’s leadership team as our new Chief Medical Officer (CMO). Dr. Dmochowski brings unparalleled expertise in urology and patient safety, with an illustrious career at Vanderbilt University and beyond. He is not only a distinguished Professor of Urology but also a leading voice in the field, serving on the editorial boards of top peer-reviewed journals. With over 230 publications, 68 book chapters, and a career defined by clinical innovation and academic excellence, Roger’s contributions have significantly advanced the field. A true pioneer in the field, Dr. Dmochowski, awarded for his work in advancing urinary incontinence treatment, will provide invaluable guidance in helping Vensica achieve its ambitious goals of delivering innovative solutions for bladder health. Roger, we are honored to have you join us. Your leadership will be instrumental as we continue to develop innovative urology therapeutics for patients worldwide. Please join me in giving a warm welcome to Dr. Roger R. Dmochowski! #Leadership #Innovation #Urology #Therapeutics

    • אין תיאור טקסט חלופי לתמונה הזו

  • ‏‏Israel Biotech Fund‏‏ פרסם מחדש את זה

    צפייה בדף הארגון של ‏The Institute of Innovation & Medicine of the Future‏
    The Institute of Innovation & Medicine of the Future

    ‏‏1,856‏ עוקבים‏

    בשבוע האחרון, פרופ' דויד סידרנסקי, הרצה בפני משתתפי.ות קורס הדירקטורים.ות בחברות HealthTech. David Sidransky רופא וחוקר מוביל ברמה הבינלאומית, בעל ניסיון עסקי נדיר בתעשיית ה-Health tech, עלה לישראל לפני כמה שנים וייסד את קרן ההון סיכון - IBF Israel Biotech Fund במהלך ההרצאה הדגיש את החשיבות של היות אחד מחברי הדירקטוריון רופא/ה, וציין כי לעיתים תפקיד ה-CMO (Chief Medical Officer), נושא עימו שכר גבוה, משכר המנכ"ל של החברה. על פי ניסיונו האישי, המסלול של רופא בהשתלבות בתפקידים כאלו הינו: * התחלה כיועץ רפואי חיצוני, לאחר מכן יועץ קבוע ומשם מעבר טבעי לדירקטוריון של החברה. באופן זה מתאפשרת למידה ומעורבות הדרגתית בחברה. * עבודה בחברה בתפקיד מחקרי, וכך להפוך להיות חלק מהחברה.   * הצטרפות לחברה כחבר בועד המנהל, תוך תרומה וניצול היכולת שיש לרופא/ה ל"תרגם" את הדברים, להוביל ולתרום לפן הקליני: מה הסיכוי שניתן לבצע מחקר קליני, מה הסיכוי שניתן לבצע ניסוי וכן הלאה.   הזדמנות טובה, להודות לפרופ' סידרנסקי על תרומתו למדינת ישראל בקידום תחומי ה- Healthtech. 8400 The Health Network Itay Friedjung The Hebrew University Business School

    • אין תיאור טקסט חלופי לתמונה הזו

  • ‏‏Israel Biotech Fund‏‏ פרסם מחדש את זה

    צפייה בדף הארגון של ‏Prism AI Therapeutics‏
    Prism AI Therapeutics

    ‏‏636‏ עוקבים‏

    Prism AI is excited to announce the appointment of Dr. David Sidransky, MD, to its board as an independent non-executive director.       Prism AI provides an end-to-end platform for (a) multi-omic data management, (b) AI and analytics for drug development, disease screening, and biomarker discovery, and (c) a biomarker system of record. As we continue to expand Prism's base of pharma and biotech customers and to scale up our service portfolio, we are honored to welcome Dr. Sidransky onto our board of directors.         Dr. Sidransky is a renowned oncologist, research scientist and serial entrepreneur. He is widely known for his research in biomarkers for early detection and therapy and is widely respected in the biopharmaceutical industry as a leading expert in oncology and precision medicine. In 2001, he was profiled in Time magazine as one of America's best people in science and medicine.      Dr. Sidransky has also accumulated extensive industry experience and exceptional expertise, not only in scientific research, but also in business operations, corporate governance and investment strategies. He is a founder of several biotechnology companies such as Champions Oncology, Inc. (Nasdaq; CSBR). Previously, he was Vice Chairman of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care, until its acquisition by Eli Lilly and Company. Dr. Sidransky is a co-founder and managing partner of the Israel Biotech Fund. He is also a highly experienced board member, having served as a director of Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), Orgenesis Inc. (Nasdaq: ORGS), Advaxis Pharmaceuticals (Nasdaq: ADXS), and Ayala (Nasdaq: AYLA).        We are confident that Dr. Sidransky’s pioneering academic work, extensive medical and scientific knowledge, and experience serving on private and public company boards will prove invaluable to Prism AI's continued growth.    Come meet us at #ASCO24 to learn more! #CureCancer #PrecisionMedicine #ClinicalTrials #ArtificialIntelligence #DataScience #MachineLearning    

דפים דומים